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Pyrrolizidine alkaloid-containing plants are widespread in the world and probably the
most common poisonous plants affecting livestock, wildlife, and humans. Pyrrolizidine
alkaloids require metabolic activation to form dehydropyrrolizidine alkaloids that bind
to cellular proteins and DNA leading to hepatotoxicity, genotoxicity, and tumorigenicity.
At present, it is not clear how dehydropyrrolizidine alkaloids bind to cellular amino acids
and proteins to induced toxicity. We previously reported that reaction of dehy-
dromonocrotaline with valine generated four highly unstable 6,7-dihydro-7-hydroxy-1-
hydroxymethyl-5H-pyrrolizine (DHP)-derived valine (DHP-valine) adducts that upon re-
action with phenyl isothiocyanate (PITC) formed four DHP-valine-PITC adduct isomers.
In this study, we report the absolute configuration and stability of DHP-valine and DHP-
valine-PITC adducts, and the mechanism of interconversion between DHP-valine-PITC
adducts.
Copyright © 2015, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.  Open access under CC BY-NC-ND license.Toxicological Research, 3900 NCTR Road, Jefferson, AR 72079, USA.
. Fu).
ministration, Taiwan. Published by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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Pyrrolizidine alkaloids are common phytochemical constitu-
ents of hundreds of plant species worldwide [1e6] and about
half of them exhibit hepatotoxic activity [2,5]. Pyrrolizidine
alkaloids are among the first naturally occurring carcinogens
identified in plants, and pyrrolizidine alkaloid-containing
plants are probably the most common type of poisonous
plants affecting livestock, wildlife, and humans [2,5]. Humans
are exposed to toxic pyrrolizidine alkaloids through staple
foods, food contaminants, herbal teas, herbal medicines, and
dietary supplements [2,5,7e12].
Pyrrolizidine alkaloids are biologically inert, requiring
metabolic activation to generate dehydropyrrolizidine alka-
loids that bind to cellular proteins and DNA, leading to
toxicity, including cytotoxicity, genotoxicity, and tumorige-
nicity [2,5]. Dehydropyrrolizidine alkaloids are highly chemi-
cally and biologically reactive, easily hydrolyze to (±)-6,7-
dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine (DHP),
react with cellular proteins to form DHP-protein adducts, and
bind to DNA to produce DHP-DNA adducts (Fig. 1) [2,5,12]. We
previously demonstrated thatmetabolismof different types of
tumorigenic pyrrolizidine alkaloids generated the same set of
DHP-derived DNA adducts in vivo, but that these DNA adducts
were not formed from the nontumorigenic pyrrolizidine al-
kaloids [6,13,14]. These results suggest that this set of DNA
adducts can serve as a common biological biomarker of pyr-
rolizidine alkaloid-induced tumorigenicity and exposure [14].
Taking monocrotaline as an example, Fig. 1 shows the meta-
bolic activation to form a dehydropyrrolizidine alkaloid that
binds to cellular proteins and DNA leading to the formation of
DHP-protein and DHP-DNA adducts and initiate cytotoxicity,
genotoxicity, and tumorigenicity.Fig. 1 e Metabolic activation of monocrotaline to form dehydrom
5H-pyrrolizine (DHP)-protein adduct and DHP-DNA adducts leadIt has been proposed that DHP-protein adducts formed
in vivo in the liver are responsible for pyrrolizidine alkaloid-
induced cytotoxicity, specifically hepatotoxicity [2,5]. Howev-
er, due to their highly unstable nature, the structures of DHP-
protein adducts have never been characterized at the molec-
ular level.With regard to DHP-amino acid adducts, 7-cysteine-
DHP [15] and DHP-valine [16] are the only two DHP-amino acid
adducts that have had their structures fully elucidated. 7-
Cysteine-DHP was prepared from the reaction of dehydrore-
tronecinewith cysteine [15]. DHP-valine adducts, consisting of
four structural isomers, were prepared by the reaction of
valine with dehydropyrrolizidine alkaloids, including dehy-
dromonocrotaline, dehydroriddelliine, and dehydroheliotrine
(Fig. 2) [16]. For structural identification, DHP-valine adducts
were converted to the corresponding isothiohydantoin (DHP-
valine-PITC) derivatives by reacting with phenyl isothiocya-
nate (PITC) [16]. DHP-valine-PITC adducts were also found
from the reaction of hemoglobin-DHP adducts with PITC
through an Edman rearrangement, which is the most
commonly employed method for quantitation of metabolite-
bound protein adducts in vivo [17]. Since DHP-valine-PITC
adducts can potentially be used for quantitation of pyrrolizi-
dine alkaloid bound protein adducts in vivo, it is important to
study their chemical properties associated with pyrrolizidine
alkaloid-induced toxicology.
We previously determined that DHP-valine adducts
formed from the above-described reactions consist of two
pairs of epimeric isomers [16]. The first pair, designated as
DHP-valine-1 and DHP-valine-3, has the amino group of
valine linked to the C9 position of the necine base, and the
other pair, DHP-valine-2 and DHP-valine-4, has the amino
group of valine linked to the C7 position of the necine base
(Fig. 2) [16]. We have also determined that DHP-valine-PITC-1
was interconvertible with DHP-valine-PITC-3, and thatonocrotaline, 6,7-dihydro-7-hydroxy-1-hydroxymethyl-
ing to cytotoxicity, genotoxicity, and tumorigenicity.
Fig. 2 e Structures, absolute configuration, and reaction of
6,7-dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine
(DHP)-valine adducts with phenyl isothiocyanate (PITC) to
form DHP-valine-PITC adducts.
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PITC-4.
As a continuation of our investigation, in this paper we
determine absolute configurations of each of the DHP-valine
and DHP-valine-PITC adducts, study the stability of DHP-
valine and DHP-valine-PITC adducts, and elucidate the
mechanism of the interconversion between DHP-valine-PITC
epimers.2. Materials and methods
2.1. Chemicals
Monocrotaline was purchased from Sigma-Aldrich (St. Louis,
MO, USA). Dimethylformamide (DMF) and PITC were obtained
from Fisher Scientific (Pittsburg, PA, USA). Acetonitrile, po-
tassium carbonate, chloroform, and diethyl ether were pur-
chased from Bio-Rad (Hercules, CA, USA).
Dehydromonocrotaline was synthesized by dehydrogenation
of monocrotaline in chloroformwith o-chloranil as previously
described [18,19]. H2
18O (isotopic purity 97%) was purchasedfrom Cambridge Isotope Laboratories, Inc. (Andover, MA,
USA). Alkaline phosphatase was acquired from Roche Di-
agnostics Corporation (Indianapolis, IN, USA).2.2. Synthesis of DHP-valine and DHP-valine-PITC
adducts
DHP-valine-PITC adducts were prepared following previously
published procedures [16]. Briefly, a solution of valine (10 mg)
and K2CO3 (10mg) in 400 mL distilledwater and 800 mL DMFwas
sonicated until the solution turned clear, and then added
drop-wise into a solution of dehydromonocrotaline (10 mg) in
1200 mL of DMF. After 2 hours, the reaction mixture was
filtered through a 0.4 mm regenerated cellulose membrane,
and products were purified by high-performance liquid chro-
matography (HPLC) with a 250 mm  10 mm Prodigy column
(Phenomenex, Torrance, CA, USA) with eluting conditions:
0e5 minutes: 2% acetonitrile in water; 5e45 minutes: 2e8%
acetonitrile in water at a flow rate of 1mL/min, andmonitored
by UV absorbance at 218 nm.
The resulting DHP-valine adducts mixture dissolved in
5 mL of acetonitrile was reacted with PITC (10 mL) under
shaking in a water bath at 45C for 48 hours. The resulting
isothiohydantoin adducts (DHP-valine-PITC) were purified by
HPLC with a Phenomenex C18 Luna (2) column
(250 mm  4.6 mm) eluted with acetonitrile in water (v/v, 43/
57) at a flow rate of 1 mL/min, and monitored at 268 nm. Each
DHP-valine-PITC adduct was characterized by comparison of
its UV absorption spectrum, HPLC retention time, mass
spectrometric data with those of the previously prepared
authentic sample [16].
For determination of the absolute configuration of the four
DHP-valine adducts, the adducts were synthesized by a
similar reaction of dehydromonocrotaline with valine.2.3. Mechanistic studies of interconversion between
DHP-valine-PITC-1 and DHP-valine-PITC-3 adducts and
between DHP-valine-PITC-2 and DHP-valine-PITC-4
To determine the mechanism of the interconversion between
DHP-valine-PITC-1 and DHP-valine-PITC-3, DHP-valine-PITC-
3 (~ 200 mg), dissolved in 100 mL acetonitrile/H2O
18 (v/v, 43/57),
was incubated at room temperature for 2 days. The resulting
DHP-valine-PITC-1 and DHP-valine-PITC-3 adducts were
separated by HPLC. HPLC conditionswere: ACE C18 AR column
(4.6 mm  250 mm, 5 mm; Mac-Mod Analytical, Inc., Chadds
Ford, PA, USA); gradient program: 0e5 minutes: 10% acetoni-
trile in H2O; 5e50 minutes: 10e18% acetonitrile in H2O; with a
flow rate of 1mL/min, andmonitored at 268 nm. The resulting
DHP-valine-PITC-1 and DHP-valine-PITC-3 adducts were
collected by HPLC for liquid chromatographyetandem mass
spectrometry (LC/MS/MS) analysis.
The study of interconversion between DHP-valine-PITC-2
and DHP-valine-PITC-4 was studied similarly by mixing
DHP-valine-PITC-4 (~200 mg) with 100 mL acetonitrile/H2
18O (v/v,
43/57) at room temperature for 2 days, and the resulting DHP-
valine-PITC-2 and DHP-valine-PITC-4 adducts were first
separated by HPLC and followed by LC/MS/MS analysis.
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DHP-valine-PITC adducts were analyzed by LC/MS/MS. The LC
system consisted of a Shimadzu Prominence HPLC system,
including a CBM-20A system controller, two LC-20AD pumps, a
SIL-20AC HT autosampler, a SPD-20A UV-visible detector (Shi-
madzu Scientific Instrument, Columbia, MD, USA), and an
automated switching valve (TPMV; Rheodyne, Cotati, CA, USA)
used to divert the column effluent to either waste or to MS in-
strument. The HPLC was coupled with an AB Sciex 4000 QTrap
LC/MS/MS system (AB Sciex, Foster City, CA, USA), equipped
with a Turbo V ion source. Desolvation temperature was set at
500C. Nitrogen was used as curtain gas, nebulizer gas, heater
gas, and collision gas. The samples were acquired in positive
IonSpray mode using MS full scan and enhanced product ion
scan. The IonSprayVoltagewas 4500V; the ion source gas 1 and
gas 2 were set to 60 and 50, respectively. The declustering po-
tential was 50 V; and the collision energy was 25 eV [16].
Each sample (10e30 mL) was loaded onto a reverse phase
column (ACE 3 C18, 2.1 mm  100 mm, 3 mm; MAC-MOD
Analytical Inc., Chadds Ford, PA, USA), with a water/acetoni-
trile gradient at 0.2 mL/min. The column chamber tempera-
ture was set to 45C. The mobile phase program: water, 0.5
minutes; a linear gradient up to 15% acetonitrile in water over
50 minutes; up to 95% in water, 1.5 minutes; and 95% aceto-
nitrile in water, 5 minutes [16].3. Results
3.1. Absolute configuration of DHP-valine products
We previously studied the reaction of dehydromonocrotaline
with valine using two different reaction times, 30minutes and
48 hours; and under both conditions, DHP-valine-1, DHP-
valine-2, DHP-valine-3, and DHP-valine-4 adducts were
formed [16]. These four DHP-valine adducts are structural
isomers and their UV-visible absorption spectra are mainly
attributed from the necine moiety. Thus, it is reasonable to
assume that they have an identical or nearly identical UV-
visible absorption molar extinction coefficient. Conse-
quently, based on HPLC peak areas of these adduct products,
the relative yields of DHP-valine adducts obtained from the
above-described reaction can be compared.
However, from the reaction of 30 minutes, all the HPLC
peak areas for each of DHP-valine adducts [16] are too small to
compare, and thus, the relative yield of these adducts could
not be determined. Further, the results from the reaction of 48
hours could not be used for determining which stereoisomer
is formed predominantly because interconversion between
isomers would occur during reaction. Therefore, in order to
determine the absolute configuration of these adducts, we
conducted the reaction of dehydromonocrotaline with valine
for 2 hours.
Previously we determined that both DHP-valine-1 and
DHP-valine-3 have the valine moiety linked to the C9 position
of the DHP base and the hydroxyl group at the C7 position
(Fig. 2), whereas DHP-valine-2 and DHP-valine-4 have the
valine moiety linked at the C7 position of the DHP base, and
the hydroxyl group sited at the C9 position (Fig. 2) [16].As the HPLC chromatogram in Fig. 3 shows, the HPLC peak
area of the DHP-valine-3 is greater than that of DHP-valine-1,
indicating that the yield of DHP-valine-3 is greater than DHP-
valine-1. Since both DHP-valine-1 and DHP-valine-3 were pro-
duced, thereactionofdehydromonocrotalinewithvalineshould
not be a pure SN2 mechanism because an SN2 mechanism pro-
duces only one enantiomer product. It is not a pure SN1 mech-
anism either, because such a mechanism would produce both
enantiomers in an equal or nearly equal quantity. Since it is
apparent that the formation of DHP-valine-1 and DHP-valine-3
adducts occurred in an unequal ratio, this suggests that adduct
formation involves a combination of SN1 and SN2 mechanisms.
An SN2 reaction produces the product with its absolute config-
uration opposite to the substrate at the reaction site, e.g., in this
case the C7 position. Thus, since dehydromonocrotaline, the
starting material of the reaction possesses a 7R absolute
configuration [2,5], the major product DHP-valine-3, should
possessa7Sabsoluteconfiguration;andtheminorproductDHP-
valine-1 should have a 7R absolute configuration.
Similarly, for the enantiomer pair DHP-valine-2 and DHP-
valine-4, the predominant product DHP-valine-2 should have
a 7S absolute configuration; and DHP-valine-4, the minor
product, holds a 7-R absolute configuration. The assigned
absolute configurations of these DHP-valine adducts are
shown in Fig. 2.
3.2. Absolute configuration of phenylthiohydantoin
(DHP-valine-PITC) adducts
Following the experimental procedure previously described
[16], the DHP-valine adduct reactionmixture was reactedwith
PITC. The resulting phenylthiohydantoin adducts, DHP-
valine-PITC-1, DHP-valine-PITC-2, DHP-valine-PITC-3, and
DHP-valine-PITC-4, were separated by reversed-phase HPLC
(Fig. 4). These adducts eluted at 17.1 minutes, 25.3 minutes,
27.2 minutes, and 29.8 minutes; and each had its UV absorp-
tion spectrum and mass spectral pattern, with preponderant
[MþNa]þ ions at m/z 392 and ions at m/z 352 corresponding to
the loss of water by the protonated adduct ([M-H2OþH]þ),
identical to those previously reported [16].
Fromeach reaction using a pure DHP-valine adduct to react
with PITC, two phenylthiohydantoin (DHP-valine-PITC) ad-
ducts were generated. The structures of the predominant
products from each reaction are shown in Fig. 2. These results
are identical to those previously published [16]. As shown in
Fig. 2, the corresponding predominant products from DHP-
valine-1, DHP-valine-2, DHP-valine-3, and DHP-valine-4 are
DHP-valine-PITC-4, DHP-valine-PITC-1, DHP-valine-PITC-2,
and DHP-valine-PITC-3, respectively. Since, in each DHP-
valine reaction, no chemical bonds of the necine base were
involved (broken) in the reaction, each predominant DHP-
valine-PITC adduct should retain the same absolute configu-
ration as that of theDHP-valine startingmaterial. The absolute
configurations of each DHP-valine-PITC are shown in Fig. 2.
3.3. Interconversion of DHP-valine-PITC-3 to DHP-
valine-PITC-1 adduct in the presence of H2
18O
To determine the mechanism of interconversion between
DHP-valine-PITC-1 and DHP-valine-PITC-3, DHP-valine-PITC-
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Fig. 3 e Reversed-phase high-performance liquid chromatography profile of four 6,7-dihydro-7-hydroxy-1-hydroxymethyl-
5H-pyrrolizine (DHP) valine adducts formed from the reactionof dehydromonocrotaline andvaline for 2hours. The conditions
for high-performance liquid chromatography: Phenomenex C18 Luna (2) column (250 mm £ 4.6 mm); flow rate: 1 mL/min;
linear gradient mobile phase: 0e10 minutes, 100% water; 10e13 minutes, 0e2% acetonitrile in water; 13e15 minutes, 2e3%
acetonitrile in water; 15e18 minutes, 3e4% acetonitrile in water; and 18e50 minutes, 4e8% acetonitrile in water.
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18O (v/v, 43/57) and kept at
room temperature for 2 days. The resulting DHP-valine-PITC-1
adduct was collected and analyzed by LC/MS. The mass
spectrum of the unlabeled DHP-valine-PITC-1 had character-
istic ions atm/z 352 ([M - H2OþH]),m/z 392 ([MþNa]), andm/z3 5 10 15 20 25 30
DHP-Val-PITC-4A
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Fig. 4 e Reversed-phase high-performance liquid
chromatography profiles of purified: (A) 6,7-dihydro-7-
hydroxy-1-hydroxymethyl-5H-pyrrolizine (DHP)-valine-
phenyl isothiocyanate (PITC)-1; (B) DHP-valine-PITC-2; (C)
DHP-valine-PITC-3; and (D) DHP-valine-PITC-4 formed
from reaction of DHP-valine mixture with PITC. High-
performance liquid chromatography conditions: Luna C18
(2) column (250 mm £ 4.6 mm, 5 mm) eluted at: 0e5
minutes, 30% acetonitrile in water; and 5e55 minutes,
30e65% acetonitrile in water at flow rate 1 mL/min,
monitored at 268 nm.136 ([DHP-OH]) (Fig. 5). The mass spectrum of the [18O] DHP-
valine-PITC-1 had characteristic ions at m/z 354 ([M -
H2O þH]),m/z 394 ([M þ Na]), andm/z 138 ([DHP-18OH]) (Fig. 5).
Comparison of the mass of these fragments ions and the
assigned structures in Fig. 5 indicates that the 18O atom is
specifically located at the 9-hydroxyl group of the necine base.3.4. Interconversion of DHP-valine-PITC-4 to DHP-
valine-PITC-2 adduct in the presence of H2
18O
Similarly, DHP-valine-PITC-4 was dissolved in acetonitrile/
H2
18O (v/v, 43/57), kept at room temperature for 2 days, and the
resulting adducts were analyzed by LC-MS. The mass spec-
trum of the unlabeled DHP-valine-PITC-2 has characteristic
ions atm/z 352 ([M - H2O þ H]),m/z 392 ([M þ Na]), andm/z 136
(Fig. 6). Themass spectrum of the [18O] DHP-valine-PITC-2 had
characteristic ions at m/z 354 ([M - H2O þ H]), m/z 394
([M þ Na]), and m/z 138 (Fig. 6). Comparison of the mass of
fragment ions as well as the assigned structures indicates that
the O18 atom is specifically located at the 7-hydroxyl group of
the necine base.4. Discussion
To date, none of the pyrrolizidine alkaloid-derived protein
adducts have had their structures characterized at the mo-
lecular level. With regard to DHP-derived amino acid adducts,
7-cysteine-DHP and DHP-valine are the only DHP-amino acid
adducts that their structures are fully elucidated [15,16].
There are four DHP-valine adduct isomers, and their struc-
tures were characterized by spectral analysis of their corre-
sponding phenylthiohydantoin derivatives, DHP-valine-PITC
Fig. 5 e Mass spectra of the [18O] 6,7-dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine-valine-phenyl isothiocyanate-1
adduct formed from mixing 6,7-dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine-valine-phenyl isothiocyanate-3 with
H2
18O.
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PITC. The most commonly employed method for identifica-
tion and quantitation of metabolite-bound protein adducts
in vivo is the reaction of hemoglobin adducts with PITC. In
this reaction, the PITC interacts at the valine terminal amino
group of the hemoglobin adducts, resulting in the replace-
ment of the hemoglobin moiety by the phenylthiohydantoin
group [17]. Thus, for identification of pyrrolizidine alkaloid-
derived protein adducts, e.g., DHP-hemoglobin adducts,
DHP-valine-PITC will be formed from the reaction of DHP-
hemoglobin adducts with PITC. Consequently, our currentstudy on the properties of DHP-valine-PITC adducts provides
a better understanding of the feasibility of using this
approach for identification and quantitation of DHP-
hemoglobin adducts in vivo.
In this study, we determined that DHP-valine-PITC-1 and
DHP-valine-PITC-2 possess a 7S absolute configuration, while
DHP-valine-PITC-3 and DHP-valine-PITC-4 have a 7R absolute
configuration (Fig. 2 and Table 1).
We previously determined that the interconversion of
DHP-valine-PITC-2 to DHP-valine-PITC-4 to give an equal ratio
required only 3 hours; while the interconversion of DHP-
Fig. 6 e Mass spectra of the [18O] 6,7-dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine-valine-phenyl isothiocyanate-2
adduct formed from mixing 6,7-dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine-valine-phenyl isothiocyanate-4 with
H2
18O.
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required 7 hours [16]. By contrast, the interconversion of DHP-
valine-PITC-1 to give a nearly equal ratio of DHP-valine-PITC-3
took 3 days; and the interconversion of DHP-valine-PITC-3 to
give a nearly equal ratio of DHP-valine-PITC-1 took 7 days [16].
Thus, the interconversion between DHP-valine-PITC-2 and
DHP-valine-PITC-4 is much faster than the interconversion
between DHP-valine-PITC-1 and DHP-valine-PITC-3 adducts.These results suggest that the stability of these adducts is in
the order: DHP-valine-PITC-3 > DHP-valine-PITC-1 > DHP-
valine-PITC-4 > and DHP-valine-PITC-2.
The interconversion between DHP-valine-PITC-2 and DHP-
valine-PITC-4 requires the dissociation/association of the
hydroxyl group at the C7 position, while the interconversion
of DHP-valine-PITC-1 andDHP-valine-PITC-3 adducts involves
the dissociation/association of the phenylthiohydantoin
Table 1 e Comparison of chemical properties of enantiomers between 6,7-dihydro-7-hydroxy-1-hydroxymethyl-5H-
pyrrolizine (DHP)-valine-phenyl isothiocyanate (PITC)-1 and DHP-valine-PITC-3 and between DHP-valine-PITC-2 and DHP-
valine-PITC-4.
Absolute configuration DHP-valine-PITC-1
7S
DHP-valine-PITC-3
7R
DHP-valine-PITC-2
7S
DHP-valine-PITC-4
7R
Polarity More polar Less polar More polar Less polar
HPLC retention time (Difference) 17.1 min (10.1 min) 27.2 min 25.3 min (4.5 min) 29.8 min
NMR chemical shift (Difference) 6.41e6.44 ppm (~0.33 ppm) 6.08 ppm 5.19e5.20 ppm (~0.08 ppm) 5.11e5.12 ppm
Stability interconversion time
(reach to equal ratio)
Less stable
3 d
More stable
6 d
Less stable
3 h
More stable
7 h
HPLC ¼ high-performance liquid chromatography; NMR ¼ nuclear magnetic resonance.
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valine-PITC adducts with the bulky phenylthiohydantoin
group sited at the C7 position (vs. the C9 position) are more
stable than the isomers possessing a hydroxyl group sited at
the C7 position.
We also analyzed the polarity of these adducts by com-
parison of their HPLC retention times shown in Fig. 4 and
nuclear magnetic resonance chemical shifts reported previ-
ously [16]. These data are listed in Table 1. Based on the
comparison of their HPLC retention times and nuclear mag-
netic resonance chemical shifts, we propose that DHP-valine-
PITC-1 is more polar than DHP-valine-PITC-3; and that DHP-
valine-PITC-2 is more polar than DHP-valine-PITC-4 (Table 1).
In the present study, we determine the mechanism of
interconversion by dissolving DHP-valine-PITC-4 in acetoni-
trile/H2
18O. LC/MS spectral analysis revealed that the resulting
DHP-valine-PITC-2 contained 18O at its C7 hydroxyl groupFig. 7 e Proposed mechanism of interconversion between 6,7-d
valine-phenyl isothiocyanate (PITC)-1 and DHP-valine-PITC-3 a(Fig. 6). These results indicate that during interconversion,
the hydroxyl group at the C7 position dissociates from the
molecule and is replaced by an 18O-containing hydroxyl
group from the H2
18O. Based on these results, we propose that
this interconversion requires only one transaction reaction
(Fig. 7).
From the reaction of DHP-valine-PITC-3 dissolved in the
presence of H2
18O, the resulting DHP-valine-PITC-1 adduct also
had the C9 hydroxyl group contain 18O. Thus, this intercon-
version involves at least two separate transitions: (1) forma-
tion of a carbonium ion at the C9 position and then regenerate
the C9 hydroxyl group by reaction with H2
18O, resulting in the
C9 18O-containing hydroxyl group; and (2) dissociation and
association of the proton at the C7 position (Fig. 7). The pro-
posed mechanism may also interpret that interconversion
between DHP-valine-PITC-1 and DHP-valine-3 takes a longer
time than that of DHP-valine-PITC-2 and DHP-valine-4.ihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine (DHP)-
nd between DHP-valine-PITC-2 and DHP-valine-PITC-4.
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